Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization
Authors | |
---|---|
Year of publication | 2007 |
Type | Article in Periodical |
Magazine / Source | Oncology Reports |
MU Faculty or unit | |
Citation | |
Field | Genetics and molecular biology |
Keywords | CGH; HR-CGH; glioblastoma multiforme; molecular cytogenetics |
Description | Comparative genomic hybridization (CGH) is a molecular cytogenetic technique that allows genome-wide analysis of DNA sequence copy number differences. We have applied conventional CGH and recently developed high resolution CGH (HR-CGH) to tumour samples from 18 patients with glioblastoma multiforme (GBM) to compare the sensitivity of CGH and HR-CGH in the screening of chromosomal abnormalities. The abnormalities were studied in topologically different central and peripheral tumour parts. A total of 78 different changes were observed using CGH (0-16 per tumour, median 3.5) and 154 different changes using HR-CGH (0-21 per tumour, median 6). Using HR-CGH, losses were more frequent than gains. The representation of the most prominent changes revealed by both methods was similar and was comprised of the amplification of 7q12-13 and 12q12-q15, the gain of 7, 3q and 19 and the loss of 10, 9p, and 13q. However, HR-CGH detected a few other abnormalities (loss of 6, 14q, 15q, and 18q and gain of 19), which were rarely revealed by CGH. Using HR-CGH, the numbers and types of chromosomal changes detected in the central and peripheral parts of GBM were almost the same. The loss of chromosomes 10 and 9p and the gain of chromosomes 7 and 19 were the most frequent chromosomal alterations in both tumour parts. Our results from GBM analysis showed that HR-CGH technology may reveal new, recurrent genetic alterations involving genes known to participate in tumorigenesis and in the progression of several human malignancies and therefore may allow for a more accurate genetic characterization of these tumours. |
Related projects: |